Stifel raised the firm’s price target on Krystal Biotech to $204 from $178 and keeps a Buy rating on the shares. Based on positive feedback from physician interviews, management commentary, and some assumption-based calculations, the firm is updating its estimates ahead of Q1 to better reflect potential disruptions, but also “a more realistic trend for the rest of 2024,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
- Biotech Alert: Searches spiking for these stocks today
- Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
- Krystal Biotech price target raised to $168 from $140 at BofA
- Krystal Biotech price target raised to $175 from $130 at Guggenheim
